The Latest Breaking News from Eli Lilly

Eli Lilly stock has surged over 1,200% in the last 10 years. Here's why I remain bullish on this blue-chip healthcare stock right now.

A new drug to treat type 2 diabetes has been approved for use) in the UK. Tirzepatide (sold under the brand name Mounjaro) could be available for prescription by early 2024 – subject to availability.

Alzheimer research made a breakthrough last month when Eli Lilly's drug donanemab slowed cognitive decline in 47% of those taking it. It follows two other drugs, lecanemab and aducanumab, that target amyloid protein buildup in the brain. However, these drugs can cause fatal brain bleeding and seizures. Oxidative stress hypothesis…

Amazon Pharmacy will automatically apply manufacturer-sponsored coupons for 15-plus products.

Before joining Tesla in July, Michael Hildebrand was executive director of projects at Eli Lilly, where he spent the previous 19 years of his career.

The main benchmarks fell Tuesday, but healthcare stocks outperformed as Eli Lilly and Novo Nordisk surged.

Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.

Since the time a human first used a tool to make life easier, increased weight has been inevitable.